Chemotherapy for the treatment of oligodendroglial tumors

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 13, 2001, Pages 13-18

  Chinot, Olivier ^a,b  

^a TIMONE HOSPITAL   (France)

^b Laboratoire IML   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0034836402     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26649     Document Type: Review

References (35)

1. Low-grade gliomas: When and how to treat
2. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
3. Neoplasms of the central nervous system
4. Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation
5. CDKN2/pl6 predicts survival in oligodendrogliomas: Comparison with astrocytomas
6. Pretreatment factors predict overall survival for patients with low-grade glioma: A recursive partitioning analysis
7. Cerebral oligodendroglioma: Prognostic factors and life history
8. Treatment and survival of low-grade astrocytoma in adults - 1977-1988
9. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria
10. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases
11. Correlation of clinical features and telomerase activity in human gliomas
12. Low-grade glial tumors in basal ganglia and thalamus: Natural history and biological reappraisal
13. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas
14. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas
15. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis
16. Proliferative activity and prognosis of low-grade astrocytomas
17. Gemistocytic astrocytomas: A reappraisal
18. Prognostic value of histologic factors in adult cerebral astrocytoma
19. Long-term outcome of low-grade oligodendroglioma and mixed glioma
20. Chemotherapy for anaplastic oligodendroglioma
21. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas
22. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
23. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy
24. Neoadjuvant procarbazine CCNU, and vincristine for anaplastic and aggressive oligodendroglioma
25. Temodal (temozolomide, TMZ) as second-line treatment following PCV in oliogodendroglial tumors
26. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas
27. Salvage chemotherapy for oligodendroglioma
28. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas
29. Oligodendroglioma: An analysis of prognostic factors and treatment results
30. Mixed oligoastrocytomas: A survival and prognostic factor analysis
31. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
32. Temozolomide in recurrent oligodendroglioma after PCV chemotherapy
33. Phase II treatment of anaplastic oligodendroglioma and low grade glioma with Temodal
34. Temozolomide chemotherapy in recurrent oligodendroglioma
35. A phase II trial of primary chemotherapy with temozolomide in patients with low-grade cerebral gliomas